Guardant Health, Inc. (GH)
Guardant Health, Inc. (GH) from its SEC filings: 2025 revenue $982.0 million (+33% vs the year before), net margin -42%, free cash flow -$233.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Services-Medical Laboratories |
| Revenue (2025) | $982.0 million |
| Revenue growth | +33% |
| Net income | -$416.3 million |
| Net margin | -42.4% |
| Free cash flow | -$233.1 million |
| Diluted EPS | $-3.32 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +44% |
| Cash | $1.1 billion |
| Long-term debt | $1.5 billion |
| Share count, 1 year | +8% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.